GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mosaic ImmunoEngineering Inc (OTCPK:CPMV) » Definitions » Equity-to-Asset

Mosaic ImmunoEngineering (Mosaic ImmunoEngineering) Equity-to-Asset : -77.91 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Mosaic ImmunoEngineering Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Mosaic ImmunoEngineering's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-6.16 Mil. Mosaic ImmunoEngineering's Total Assets for the quarter that ended in Mar. 2024 was $0.08 Mil.

The historical rank and industry rank for Mosaic ImmunoEngineering's Equity-to-Asset or its related term are showing as below:

CPMV' s Equity-to-Asset Range Over the Past 10 Years
Min: -77.91   Med: 0.89   Max: 0.99
Current: -77.91

During the past 13 years, the highest Equity to Asset Ratio of Mosaic ImmunoEngineering was 0.99. The lowest was -77.91. And the median was 0.89.

CPMV's Equity-to-Asset is ranked worse than
99.49% of 1561 companies
in the Biotechnology industry
Industry Median: 0.67 vs CPMV: -77.91

Mosaic ImmunoEngineering Equity-to-Asset Historical Data

The historical data trend for Mosaic ImmunoEngineering's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mosaic ImmunoEngineering Equity-to-Asset Chart

Mosaic ImmunoEngineering Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 0.78 -10.41 -18.72 -32.62

Mosaic ImmunoEngineering Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.66 -14.24 -19.51 -32.62 -77.91

Competitive Comparison of Mosaic ImmunoEngineering's Equity-to-Asset

For the Biotechnology subindustry, Mosaic ImmunoEngineering's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mosaic ImmunoEngineering's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mosaic ImmunoEngineering's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Mosaic ImmunoEngineering's Equity-to-Asset falls into.



Mosaic ImmunoEngineering Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Mosaic ImmunoEngineering's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-5.871/0.18
=

Mosaic ImmunoEngineering's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=-6.155/0.079
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mosaic ImmunoEngineering  (OTCPK:CPMV) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Mosaic ImmunoEngineering Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Mosaic ImmunoEngineering's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Mosaic ImmunoEngineering (Mosaic ImmunoEngineering) Business Description

Traded in Other Exchanges
N/A
Address
1537 South Novato Boulevard, Suite 5, Novato, CA, USA, 94947
Mosaic ImmunoEngineering Inc is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. The company has a single operating segment for the purposes of assessing performance and making operating decisions.
Executives
Robert Baffi director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Case Western Reserve University 10 percent owner 10900 EUCLID AVENUE, CLEVELAND OH 44106
Steven W King director, officer: President and CEO
Paul J Lytle director, officer: EVP, Chief Financial Officer
Robert L Garnick director C/O PATRIOT SCIENTIFIC, 2038 CORTE DEL NOGAL, SUITE 141, CARLSBAD CA 92011
Nicole Franziska Steinmetz director, officer: Chief Scientific Officer 871 WILBUR AVENUE, SAN DIEGO CA 92019
Dharmesh Mistry director 315 PEMBROKE COURT, SAN RAMON CA 94582
Carlton M Johnson director
Donald E Schrock director C/O INTEGRATED DEVICE TECHNOLOGY, INC., 6024 SILVER CREEK VALLEY ROAD, SAN JOSE CA 95138
Paul R Bibeau officer: VP, Business Development MICROSEMI CORP, 2381 MORSE AVE, IRVINE CA 92614
Frederick C Goerner officer: Chief Executive Officer MICROSEMI CORPORATION, ONE ENTERPRISE, ALISO VIEJO CA 92656
Clifford L Flowers officer: Chief Financial Officer C/O BAKBONE SOFTWARE, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Harry L Tredennick director 6183 PASEO DEL NORTE #180, CARLSBAD CA 92011
Thomas J Sweeney officer: CFO
Helmut Jr Falk director

Mosaic ImmunoEngineering (Mosaic ImmunoEngineering) Headlines